Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Frequently asked questions
What sector does Climb Bio Inc (CLYM) operate in?
Climb Bio Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Climb Bio Inc (CLYM) current stock price?
As of the latest data, Climb Bio Inc stock price is $17.39, with a previous close of $17.44. Climb Bio Inc lost -$0.05 in the last trading session, representing a -0.29% loss.
What is Climb Bio Inc (CLYM) current market capitalization?
Climb Bio Inc market cap is approximately 998.82 million.
What is Climb Bio Inc (CLYM) Earnings Per Share (EPS)?
The trailing EPS is -$0.82, and the forward EPS is -$1.06.
What is Climb Bio Inc (CLYM) EBITDA?
Climb Bio Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -15.33 million.
Does Climb Bio Inc (CLYM) pay dividends?
No. Climb Bio Inc does not pay a dividend.
What is Climb Bio Inc (CLYM) beta (volatility) score?
Climb Bio Inc has a beta of 0.084, indicating lower volatility than the overall market.
